600 patients66,869 observations120 daysLIVE

Patient P-01627

Synthetic patientNBL-101 · Day 114 · 35–44 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
60%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 48 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 56 GI-04 recommendedGI Support Protocol GI-04
  4. Day 57 Patient acceptedStarted GI-04 in the companion
  5. Day 65 GI symptom burden −30% vs expectedGI Support Protocol GI-04
  6. Day 71 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days
  • GI instability-21
  • Nutritional resilience+19
  • Inflammatory activity-9
  • Toxicity+9
  • Treatment adherence+7

What helped?

  • GI Support Protocol GI-04Day 56
    Result: symptom burden −30%
LIFE OS recommendation
Dietary Support Protocol NP-02
54%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
46.2/100
stable · -1.5 vs previous 14 d
Toxicity
Blood
46.6/100
worsening · +2.3 vs previous 14 d
Sleep quality
Wearable
14.4/100
worsening · -2.7 vs previous 14 d
Energy level
Daily log
2.9/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log
6.2/10
stable · +0.1 vs previous 14 d
Steps
Wearable
6,354
stable · +85 vs previous 14 d
Adherence
Companion
58.4 %
stable · +1.8 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 40 from the failing basin, 48 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 64%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 64%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 64%
Would not help
  • Keep fat low
    GI +5.3 next day on high-intake days · n 20
  • Keep histamine low
    GI +4 next day on high-intake days · n 19
  • Keep simple carbs low
    GI +3.4 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.3detractor · 95%
  • Histamine load
    +4detractor · 95%
  • Simple carbohydrates
    +3.4detractor · 81%
  • Insoluble fibre
    +1.4no signal · 30%
  • Spicy / capsaicin
    +0.7no signal · 16%
  • Alcohol
    +0.4no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 53
    • WearableHRV 28 ms, trending down
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 46 and rising
    • WearableSleep 5.7 h, below personal baseline
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 39/100
    • MicrobiomeF. prausnitzii depleted
  • Drug metabolism and exposure 20
    • BloodToxicity index 47
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Rapid metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.7 · butyrate capacity 39/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
31 ms
Sleep
5.9 h
Steps
5,085
Resting HR
74 bpm
Daily log: GI score 46, nutritional resilience 51, adherence 58.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0170662%S14GI-04improved55
P-0162458%S14GI-04improved52
P-0143857%S14GI-04improved56
P-0187957%S14SC-12improved51
P-0155654%S14GI-04improved44
P-0132352%S14GI-04improved50
P-0136551%S14SC-12improved49
P-0140051%S17GI-04improved51
P-0139350%S14GI-04improved53
P-0147350%S14GI-04improved51
P-0154350%S14GI-04improved54
P-0157350%S14GI-04improved49